News Breaks |
|
|
| February 28, 2013 |
| 16:08 EDT |  | SLXP | Salix sees Q1 non-GAAP EPS 63c, consensus 69c
Sees Q1 revenue $200M, consensus $206.14M. |
|
|
News For SLXP From The Last 14 Days Check below for free stories on SLXP the last two weeks. |
|
|
| May 23, 2013 |
| 12:35 EDT |  | SLXP | Salix management to meet with Jefferies
 Subscribe for More Information |
|
| May 22, 2013 |
| 07:07 EDT |  | SLXP | Salix announces statistically significant results for budesonide foam
Salix Pharmaceuticals announced the successful completion and outcome of two pivotal Phase 3 studies to evaluate the efficacy and safety of budesonide foam in the treatment of active mild to moderate ulcerative proctitis, UP, or ulcerative proctosigmoiditis, UPS. In each of the two pivotal Phase 3 studies, a statistically significant proportion of subjects treated with budesonide foam achieved clinical remission compared to subjects treated with placebo foam. The company said, “We are pleased with the outcome of our pivotal studies of budesonide foam in the treatment of UP and UPS...We believe foam formulations provide important advantages over enema formulations principally with respect to drug retention and patient acceptance. We are working to submit a New Drug Application for budesonide foam as a treatment for UP and UPS by the end of September 2013. If approved, budesonide foam would be the first foam product approved in the United States for patients with UP...as well as for patients suffering from UPS." |
|
| May 17, 2013 |
| 10:36 EDT | | SLXP | Leerink's major/specialty pharma analyst holds analyst/Industry conference call
Subscribe for More Information |
|
| May 10, 2013 |
| 10:00 EDT |  | SLXP | On The Fly: Analyst Downgrade Summary
Subscribe for More Information |
|
| 08:07 EDT |  | SLXP | Salix price target raised to $57 from $53 at Brean Capital
Subscribe for More Information |
|
| 06:31 EDT | | SLXP | Salix downgraded to Neutral from Buy at Janney Capital
Subscribe for More Information |
|
|
|
|
|
